BioSpace News Archive

CooperSurgical, a global leader in fertility and women’s health, announced that Cord Blood Registry® will have a key role in the upcoming Cord Blood Connect meeting from September 8th – 11th, which is the annual meeting of the Cord Blood Association.

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY, on Wednesday, September 13, 2023, which includes a presentation beginning at 2:55 pm ET.

Bio-Path Holdings, Inc., (NASDAQ:BPTH) today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 25th Annual Global Investment Conference made available on Monday, September 11, 2023 at 7:00 a.m. ET.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the risk stratification performance of its TissueCypher® test in an oral presentation during the Presidential Plenary Session of the 19th ISDE World Congress for Esophageal Diseases, being held Sept. 8-10 in Toronto, Canada.

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore.

Novavax, Inc. announced that Novavax granted non-qualified stock options and restricted stock units to Ian Watkins, Executive Vice President and Chief Human Resources Officer, as a material inducement for their entry into employment with Novavax.

Cingulate Inc. announced that Werth Family Investment Associates, LLC, the manager of which is Peter J. Werth, a member of the Cingulate board of directors, has converted $5.8 million of debt and accrued interest into Cingulate equity, at a conversion price of $0.85 per share.

Regeneron Pharmaceuticals, Inc. announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024.

Parion Sciences Inc. today announced publication in The Lancet Respiratory Medicine of positive results of the Phase 2 study of idrevloride in hypertonic saline in people with primary ciliary dyskinesia (PCD).

Molybdenum disulfide (MoS2) has recently garnered attention among materials science researchers owing to its ability to form two-dimensional nanosheets like graphene.